Lilly Adds Another Alzheimer’s Bet With $1bn Push Into Amyloid Modulation

Eli Lilly has signed a licensing deal worth up to $1bn with Swedish biotech AlzeCure Pharma for ACD680, a preclinical Alzheimer’s programme targeting amyloid-beta production via gamma-secretase modulation.

The move extends Lilly’s growing presence in Alzheimer’s disease and adds a complementary approach to its existing anti-amyloid therapy Kisunla (donanemab), shifting part of its focus further upstream in disease biology.

A Shift From Removal To Modulation

ACD680 is a small molecule gamma-secretase modulator designed to alter how amyloid precursor proteins are processed.

Instead of directly clearing amyloid plaques, it aims to reduce production of Aβ42, a peptide associated with plaque formation, while increasing shorter amyloid-beta fragments such as Aβ37 and Aβ38, which are considered less toxic.

The concept sits within a long-standing but still active hypothesis in Alzheimer’s research: that changing amyloid production early in the disease cascade may offer a more durable disease-modifying effect.

Deal Structure

The agreement includes:

• $10m upfront payment

• Up to ~$990m in development and commercial milestones

• Mid-single digit royalties on future sales
  

Lilly secures global rights to ACD680, while AlzeCure retains upside through milestone and royalty participation.

Why This Matters For Lilly

The deal strengthens Lilly’s Alzheimer’s strategy at a time when the field remains both commercially important and scientifically contested.

Kisunla positioned Lilly in the anti-amyloid antibody space, but outcomes across the class continue to generate debate around the magnitude of clinical benefit in real-world settings.

Despite this, amyloid remains the dominant biological target in Alzheimer’s drug development, with dozens of active programmes continuing to pursue variations of the same pathway.

ACD680 represents a complementary angle rather than a replacement strategy, broadening Lilly’s exposure across multiple points in amyloid biology.

Part Of A Broader Dealmaking Wave

The Alzheimer’s agreement is one of several major transactions Lilly has signed in 2026, reflecting a sustained external innovation strategy across multiple therapeutic areas.

Recent deals include:

• A $1.9bn RNA exon editing partnership with Ascidian Therapeutics

• A $1.26bn GLP-2 licensing deal with Hanmi Pharmaceutical

• A $3bn collaboration with Haisco Pharmaceutical Group

• $3.83bn in vaccine-related acquisitions across multiple biotech companies
  

The pattern reflects a clear shift towards building breadth across modalities through structured, milestone-driven partnerships.

Summary

The $1bn AlzeCure deal reinforces Lilly’s continued commitment to Alzheimer’s disease while expanding its strategy from antibody-based plaque targeting into earlier-stage modulation of amyloid production.

More broadly, it underscores how large pharma is increasingly building pipelines through layered, multi-modal external innovation rather than single-platform dependence.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com